The company said its Potassium Phosphates Injection is bioequivalent and therapeutically equivalent to the reference listed drug from Fresenius Kabi. Glenmark plans to begin distribution of the product in March 2026.
The company said its Potassium Phosphates Injection is bioequivalent and therapeutically equivalent to the reference listed drug from Fresenius Kabi. Glenmark plans to begin distribution of the product in March 2026.